BeOne Medicines Q3 2025 revenue surges to $1.4bn, exceeds targets

BeOne Medicines Ltd. announced its unaudited Q3 2025 results, reporting a 41% increase in total revenues to $1.4 billion compared to Q3 2024. This surpassed its full-year revenue guidance of $5.1 billion to $5.3 billion. Global BRUKINSA® (zanubrutinib) revenues grew 51% to $1.0 billion. The company recorded a GAAP net income of $124.8 million for Q3 2025, a significant improvement from a $(121.350) million loss in Q3 2024, with diluted GAAP EPS of $1.09.

In a strategic move on August 25, 2025, BeOne Medicines I GmbH entered into a royalty purchase agreement to sell future royalty rights on worldwide sales of Amgen’s IMDELLTRA® for up to $950,000 to Royalty Pharma Investments 2023 ICAV, receiving an upfront payment of $885,000. This transaction is classified as a financing liability and is amortized using the effective interest method. Operating expenses are expected to track with GAAP expenses, maintaining a mid-to-high 80% gross margin.

Regulatory milestones include FDA Breakthrough Therapy Designation for sonrotoclax and EC approval for TEVIMBRA. The company also filed a waiver of certain rights related to distracting product restrictions under its collaboration agreement with Amgen, effective August 11, 2025. BeOne is actively advancing its pipeline, with Phase 3 trials initiated for sonrotoclax and BGB-16673, and a Phase 2 trial for BGB-45035, while maintaining a strong cash position of $4,110,542 as of September 30, 2025.